CheckMate-057

一行要約

プラチナ既治療の非扁平上皮 NSCLC 2L における Nivolumab vs Docetaxel の phase III。OS HR 0.73 (12.2 vs 9.4 mo) で有意に OS を延長し、非扁平上皮 NSCLC における IO 承認を導いた。CheckMate-017 (扁平上皮) と異なり、PD-L1 高発現群で benefit が顕著であった点が biomarker-selected IO 戦略の根拠となった。

試験デザイン

• 対象: Stage IIIB/IV 非扁平上皮 NSCLC、プラチナ製剤を含む 1 レジメン後に進行、ECOG PS 0-1、N=582 (1:1)
• 介入群 (n=292) : Nivolumab 3 mg/kg Q2W
• 対照群 (n=290) : Docetaxel 75 mg/m2 Q3W
• 層別化: 先行治療ライン数 (2L vs 3L)、地域
• 主要評価項目: OS
• EGFR/ALK: Driver mutation 陽性例は TKI 既治療を要件として許容

主要結果

• OS (primary) : HR 0.73 (96% CI 0.59–0.89, p=0.002)、median 12.2 vs 9.4 mo
• 1-year OS rate: 51% vs 39%
• PFS: HR 0.92 (95% CI 0.77–1.11, p=0.39)、median 2.3 vs 4.2 mo — PFS は有意差なし (早期進行例あり)
• ORR: 19% vs 12% (p=0.02)
• PD-L1 別解析: PD-L1 ≥1% で OS HR 0.59、PD-L1 ≥5% で HR 0.43、PD-L1 ≥10% で HR 0.40。PD-L1 <1% では OS HR 0.90 (有意差なし)
• Grade 3-5 AE: Nivolumab 10% vs Docetaxel 54%

臨床的意義

• 非扁平上皮 NSCLC における IO 承認根拠: CheckMate-017 (扁平上皮) に続く組織型拡大で、NSCLC 2L 全体の IO 標準化を完成
• PD-L1 biomarker の重要性: 扁平上皮 (CM-017) では PD-L1 非依存であったのに対し、非扁平上皮では PD-L1 発現が効果予測因子。この違いは KEYNOTE-010 の PD-L1 cutoff 選択や KEYNOTE-042 の TPS ≥1% 設定に影響
• PFS-OS 乖離: PFS で差がつかなかったにもかかわらず OS で有意差を示した IO 特有の late separation curve を初めて大規模に示した
• 5-year follow-up: 5-year OS rate 約14% (Docetaxel 約8%) で long-term survivor の存在を確認

Open Questions

• IO 既治療後の 2L 治療パラダイム: 1L IO+化療普及により IO-naive 2L は希少化。IO 後 2L 最適治療の確立が喫緊
• PD-L1 <1% 非扁平上皮の最適 2L: 本試験で benefit が乏しかった群への代替戦略
• TMB / STK11 / KEAP1 / TP53 の層別化: molecular subtype に基づく IO 効果予測の精緻化

重要論文 Top 10

1. Borghaei et al. NEnglJMed 2015 — Primary publication — OS HR 0.73、非扁平上皮 2L IO 根拠
2. Brahmer et al. NEnglJMed 2015 (CheckMate-017) — 扁平上皮 companion — 組織型別 PD-L1 依存性の対比
3. Borghaei et al. JClinOncol 2021 — 5-year OS follow-up — long-term benefit の確認
4. Horn et al. NEnglJMed 2018 (CheckMate-227 Part 1) — 1L IO+IO — 2L IO 知見の 1L 展開
5. Vokes et al. (pooled analysis) — CheckMate-017/057 pooled — long-term OS、response duration

関連エンティティ・概念

• 薬剤: Nivolumab / Docetaxel
• 関連試験: CheckMate-017 (扁平上皮 2L) / KEYNOTE-010 (Pembrolizumab 2L) / CheckMate-227 (1L IO+IO) / KEYNOTE-189 (1L 非扁平上皮 IO+化療)
• 関連遺伝子: PD-L1 / EGFR / ALK
• 関連概念: irAE
• ドメイン: lung-cancer-treatment

関連論文

直近 30 件のみ表示中 (関連 55 件)。 全件は MOC ページ または Obsidian (source Markdown) から辿れます。

Basic-Brain metastasis

• Bongiovanni et al. FrontImmunol 2021 — Immune checkpoint inhibitors with or without bone-targeted therapy in NSCLC patients with bone metastases and
• Landi et al. JImmunotherCancer 2019 — Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer

Basic-Immunotherapy

• Havel et al. NatRevCancer 2019 — The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy

Basic-Neutrophil and myeloid cell

• LoRusso et al. ClinCancerRes 2019 — Antibody-FcFcR interaction on macrophages as a mechanism for hyperprogressive disease in non-small cell lung cancer
• Sekine et al. LungCancer 2018 — Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in
• Schalper et al. NatMed 2020 — Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of

Clinical-NSCLC-Driver negative

• Skoulidis et al. CancerDiscov 2018 — STK11LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma
• Doroshow et al. ClinCancerRes 2019 — Immunotherapy in non-small cell lung cancer facts and hopes
• Carbone et al. ESMOOpen 2025 — Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung
• Horn et al. EurJCancer 2018 — Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer final results from a
• Gettinger et al. JClinOncol 2018 — Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer results from the CA209-003
• Passaro et al. JClinOncol 2019 — Immunotherapy in non-small-cell lung cancer patients with performance status 2 clinical decision making with scant
• Waterhouse et al. JClinOncol 2020 — Continuous versus 1-year fixed-duration nivolumab in previously treated advanced non-small-cell lung cancer CheckMate
• Borghaei et al. JClinOncol 2021 — Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057 nivolumab versus docetaxel in previously
• Kato et al. JImmunotherCancer 2020 — Propensity score-weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with
• Spigel et al. JThoracOncol 2019 — Safety, efficacy, and patient-reported health-related quality of life and symptom burden with nivolumab in patients
• Crino et al. LungCancer 2019 — Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer
• Socinski et al. NEnglJMed 2018 — Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC
• Barlesi et al. OncoImmunology 2020 — Effectiveness and safety of nivolumab in the treatment of lung cancer patients in france preliminary results from the
• Barlesi et al. OncoImmunology 2025 — Final 3-year results from the EVIDENS study, an observational study of nivolumab in non-small cell lung cancer
• Cengiz et al. SciRep 2026 — Comparison of flat-dose versus weight-based dose nivolumab treatment in NSCLC patients

Clinical-NSCLC-EGFR

• Yoshida et al. AnnOncol 2018 — Nivolumab in non-small-cell lung cancer with EGFR mutation
• Niu et al. FrontImmunol 2026 — Efficacy and mechanisms of immune checkpoint inhibitors in late-stage EGFR-mutated non-small cell lung cancer following
• Oshima et al. JAMAOncol 2018 — EGFR-TKI-associated interstitial pneumonitis in nivolumab-treated patients with non-small cell lung cancer
• Garassino et al. JThoracOncol 2018 — Italian nivolumab expanded access program in nonsquamous non-small cell lung cancer patients results in never-smokers
• Soo et al. LungCancer 2018 — Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer current

Clinical-SCLC

• Tian et al. JHematolOncol 2019 — Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small

Clinical-Supportive care

• Blayney et al. JAMAOncol 2020 — Efficacy of plinabulin vs pegfilgrastim for prevention of chemotherapy-induced neutropenia in adults with non-small

Clinical-irAE

• Sata et al. CancerSci 2021 — Treatment and relapse of interstitial lung disease in nivolumab-treated patients with non-small cell lung cancer
• Shankar et al. JAMAOncol 2020 — Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non-small cell